Discussions by the Ministry of Health, Labor and Welfare’s (MHLW) study group on the generic industry structure are reaching the last lap. Its final report - a draft of which will be presented later this month - is expected to…
HOME > BUSINESS
BUSINESS
- Break of Day-Working to Optimize Settai Practices, Increase Financial Transparency: 2
March 19, 2012
- Nichi-Iko Definitely to Enter as Global Top-10 Generics Company within 4 Years: President Tamura
March 16, 2012
- Fuji-Keizai Predicts Japan’s Generics Market to Exceed ¥580 Billion in 2014
March 16, 2012
- All-Case PMS for Sutent Lifted: Pfizer
March 16, 2012
- Eli Lilly Japan Looks at Double-Digit Growth Despite Large Price Cuts in 2 Mainstay Drugs: President Zulueta
March 16, 2012
- Teva-Kowa, Taiyo, Nippon Kayaku Apply for Approval of Gran Biosimilar
March 15, 2012
- Shionogi Submits Clinical Trial Application in Europe for OncoTherapy’s Cancer Vaccine
March 15, 2012
- Nichi-Iko Makes Yakuhan Its Subsidiary, Acquiring 69% of Company’s Stock
March 15, 2012
- Qol to Appoint Daiichi Sankyo Espha Chairman as Managing Director
March 15, 2012
- Nichi-Iko Announces New Med-Term Management Plan, Targets ¥130 Billion Sales in Mar 2016
March 15, 2012
- Baxter Reports Temporary Suspension in Shipments of Albumin Products to Japan
March 15, 2012
- MR Survey Shows Number of Doctors Visited, Detailing Activity Downtrend
March 14, 2012
- Pharmacists Rate Pfizer Highly for Generic Selection: Survey
March 14, 2012
- Nihon Chouzai to Provide Generic Drug Information System to Pharmacies of Other Companies
March 14, 2012
- Astellas and UMN Announce Favorable Phase II Results for Influenza HA Vaccine
March 14, 2012
- Sawai’s Next Midterm Management Plan Aims to Create a “Muscular Company”: Pres. Sawai
March 14, 2012
- MediciNova Obtains Notice of Patent Allowance for Ibudilast for Treatment of Chronic Neuropathic Pain
March 14, 2012
- Pfizer Reports 19% Boost in Sales in FY2011, “Continued Growth Possible” After Re-Pricing
March 13, 2012
- Upcoming Reforms “Ideal” for Promoting Use of Generic Drugs: President Sawai of Sawai Pharm.
March 13, 2012
- Nippon Shinyaku and Taiho to Cancel Licensing Agreement for Novel Antipruritic Agent
March 12, 2012
ページ
Whenever an excellent employee or leader leaves, it’s a blow to your organization.The departure of staff is an inevitable part of business, but in a fiercely competitive recruitment landscape like Japan, employee retention is a priority.Not only does retaining staff…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…